Phage Therapy Market Size, Share, Growth, Trends, Global Industry Analysis By Type (DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage, and Others), By Application (Animal Health, Aquaculture, Agriculture, Food Industry, Human Health, and Others), Regional Insights and Forecast From 2026 To 2035

• 

  Download Free Sample to learn more about this report

PHAGE THERAPY MARKET OVERVIEW

Starting at USD 0.06 Billion in 2026, the global Phage Therapy Market is set to witness notable growth. By 2035, it is projected to reach USD 0.22 Billion. The market is expected to expand at a CAGR of 17.6% throughout the forecast period from 2026 to 2035.

The phage therapy market is expanding rapidly due to increasing antimicrobial resistance cases and rising demand for precision antibacterial treatments. In 2024, more than 4.95 million deaths globally were associated with antimicrobial-resistant bacterial infections, accelerating research into bacteriophage-based therapeutics. DsDNA bacteriophages accounted for 67% of therapeutic phage research programs because of their high bacterial specificity and genome stability. Human health applications represented 54% of total phage therapy development activities globally during 2024. More than 180 active clinical and preclinical phage therapy programs were recorded worldwide. Increased regulatory support for compassionate phage therapy use and advancements in genomic sequencing technologies further strengthened phage therapy market development.

The United States remained a major center for phage therapy research and clinical development during 2024. More than 48 active bacteriophage clinical studies were underway across U.S. biotechnology firms, universities, and healthcare institutions. Human health applications represented nearly 58% of total domestic phage therapy activities due to increasing multidrug-resistant bacterial infections. The Centers for Disease Control and Prevention estimated over 2.8 million antibiotic-resistant infections annually in the country. Precision phage cocktails targeting Pseudomonas aeruginosa and Staphylococcus aureus accounted for 44% of ongoing therapeutic programs. Government-supported antimicrobial resistance initiatives and biotechnology investments increased phage therapy research collaborations by 23% during 2024.

KEY FINDINGS

LATEST TRENDS

Multipurpose Developments to Benefit Market Prospects

The phage therapy market is witnessing rapid innovation through precision bacteriophage engineering, AI-assisted microbial targeting, and personalized antibacterial treatments. During 2024, more than 180 active phage therapy clinical and preclinical programs operated globally, reflecting rising interest in alternatives to conventional antibiotics. Personalized phage cocktails targeting multidrug-resistant pathogens increased by 34% during 2024 due to improved bacterial genome sequencing capabilities. AI-integrated bacteriophage screening platforms improved pathogen identification accuracy by 29%, accelerating therapeutic development timelines. Human health applications remained dominant, accounting for 54% of total phage therapy activities globally. Hospitals and research institutions increasingly utilized compassionate-use phage therapies for severe bacterial infections resistant to multiple antibiotic classes.

More than 48 active phage therapy studies were underway in the United States during 2024. Food safety applications also gained momentum, with bacteriophage products reducing Salmonella contamination rates by 31% in food processing environments. Synthetic biology technologies enabled engineered phages with enhanced bacterial targeting efficiency exceeding 92% in laboratory studies. Aquaculture and animal health industries increasingly adopted phage therapies to reduce antibiotic usage in livestock production systems. Europe expanded regulatory support for experimental bacteriophage treatments, while Asia-Pacific increased investments in microbial biotechnology research facilities. Genomic sequencing costs also declined by 18%, improving accessibility for precision phage therapy development globally.

Download Free Sample to learn more about this report

PHAGE THERAPY MARKET SEGMENTATION

By Type

Based on type, the market is divided into DsDNA Bacteriophage, SsDNA Bacteriophage, SsRNA Bacteriophage, and Others. DsDNA Bacteriophage segment is anticipated to hold maximum share during 2032.

• DsDNA Bacteriophage: DsDNA bacteriophages accounted for approximately 67% of total phage therapy research and commercial development activities during 2024. These bacteriophages demonstrated superior genetic stability and high bacterial specificity in therapeutic applications targeting multidrug-resistant pathogens. More than 58% of ongoing human clinical bacteriophage programs utilized dsDNA phages because of their efficient bacterial lysis mechanisms and stable genome structure. Laboratory studies indicated bacterial elimination effectiveness exceeding 91% against selected antibiotic-resistant strains including Staphylococcus aureus and Klebsiella pneumoniae. Synthetic biology technologies also improved dsDNA bacteriophage engineering precision by 26% during 2024. North America and Europe remained major research centers for dsDNA bacteriophage development due to strong biotechnology infrastructure and clinical research funding. 

• SsDNA Bacteriophage: SsDNA bacteriophages represented approximately 14% of global phage therapy research activities during 2024. These bacteriophages gained increasing attention in microbial genetics, biosensing, and targeted bacterial modulation studies. SsDNA bacteriophages demonstrated strong adaptability in laboratory-based bacterial detection systems and synthetic biology applications. Biotechnology firms increased ssDNA bacteriophage research funding by 18% during 2024 due to growing interest in precision microbial engineering. Human health applications involving gastrointestinal infections and bacterial biofilm disruption represented major research areas for ssDNA bacteriophages. AI-assisted genomic analysis improved ssDNA phage screening efficiency by 22%, accelerating therapeutic selection processes.

• SsRNA Bacteriophage: SsRNA bacteriophages accounted for approximately 9% of phage therapy research programs during 2024 due to their relevance in molecular biology and vaccine development applications. These phages demonstrated rapid replication cycles and strong adaptability for microbial genetic studies. Research laboratories increasingly utilized ssRNA bacteriophages in RNA-targeting therapeutic research and antimicrobial resistance monitoring programs. Academic institutions expanded ssRNA bacteriophage studies by 16% during 2024 to support synthetic biology innovation and microbiome research. Europe and North America remained major regions for ssRNA phage-related biotechnology development due to advanced molecular biology infrastructure. Food safety and agricultural biotechnology sectors also explored ssRNA bacteriophages for bacterial pathogen detection systems. 

• Others: Other bacteriophage categories including filamentous phages and engineered synthetic phages represented nearly 10% of global phage therapy development activities during 2024. Synthetic engineered phages demonstrated bacterial targeting efficiency exceeding 92% in controlled laboratory environments. Biotechnology companies increasingly developed modified bacteriophages with enhanced bacterial binding and resistance-avoidance capabilities. Research into CRISPR-integrated phage technologies increased by 21% during 2024 as scientists explored precision microbial gene editing applications. Environmental and industrial biotechnology sectors also investigated engineered bacteriophages for wastewater treatment and microbial contamination control systems. 

By Application

Based on application, the market is bifurcated into Animal Health, Aquaculture, Agriculture, Food Industry, Human Health, and Others. Animal health segment is projected to dominate the market share through 2032.

• Animal Health: Animal health applications represented approximately 18% of total phage therapy activities during 2024 due to rising concerns regarding antibiotic overuse in livestock production. Poultry and cattle industries increasingly adopted bacteriophage products to reduce bacterial infections and improve biosecurity measures. Phage-based livestock treatments reduced Salmonella prevalence by 27% in poultry production environments during laboratory and field studies. Europe expanded restrictions on antibiotic growth promoters, encouraging alternative microbial control strategies within animal agriculture. Veterinary biotechnology companies increased phage therapy research programs by 19% during 2024. 

• Aquaculture: Aquaculture applications accounted for approximately 11% of the global phage therapy market during 2024 due to increasing disease outbreaks in fish farming operations. Phage-based antimicrobial solutions reduced Vibrio bacterial infections by 33% in aquaculture production systems. Asia-Pacific represented the largest aquaculture phage therapy market because of extensive seafood farming infrastructure across China, Vietnam, and Indonesia. Aquaculture producers increasingly adopted bacteriophage therapies to reduce antibiotic dependency and improve export compliance with international food safety standards. Biotechnology firms expanded aquatic microbial research investments by 17% during 2024. 

• Agriculture: Agriculture applications represented nearly 9% of total phage therapy activities during 2024 due to increasing demand for sustainable crop protection solutions. Bacteriophage products targeting Xanthomonas and Pseudomonas plant pathogens reduced crop infection rates by 28% across greenhouse and field agriculture environments. Organic farming operations increasingly integrated phage-based bacterial control methods to minimize chemical pesticide usage. North America and Europe expanded agricultural biotechnology research focused on phage-mediated plant disease management during 2024. Controlled-environment agriculture facilities improved bacterial contamination management efficiency by 19% through bacteriophage applications. 

• Food Industry: The food industry represented approximately 15% of global phage therapy market activity during 2024 due to increasing bacterial food contamination concerns. Bacteriophage products targeting Salmonella, Listeria monocytogenes, and Escherichia coli reduced foodborne pathogen contamination by 31% in processing facilities. Meat, dairy, and packaged food manufacturers increasingly adopted phage-based microbial safety solutions to strengthen food quality standards. Food safety authorities across North America and Europe approved several bacteriophage products for commercial food processing applications during 2024. Cold-chain food transportation systems also integrated bacteriophage technologies to minimize microbial contamination risks. 

• Human Health: Human health remained the dominant phage therapy application segment with 54% of total market activity during 2024. More than 48 active bacteriophage clinical studies operated in the United States during the year, primarily targeting multidrug-resistant bacterial infections. Compassionate-use phage therapy programs expanded by 28% globally due to increasing antimicrobial resistance cases. Hospitals and infectious disease centers increasingly investigated bacteriophage treatments targeting Pseudomonas aeruginosa, Staphylococcus aureus, and Acinetobacter baumannii infections. Personalized phage cocktail therapies improved bacterial elimination effectiveness by 37% in selected clinical studies. 

• Others: Other phage therapy applications including environmental biotechnology, wastewater treatment, and industrial microbial control represented approximately 13% of total market activity during 2024. Wastewater treatment facilities increasingly adopted bacteriophage technologies to reduce bacterial contamination and biofilm formation in industrial water systems. Environmental biotechnology projects integrating engineered phages improved microbial control efficiency by 23%. Industrial biotechnology firms expanded bacteriophage-based microbial management systems within pharmaceutical manufacturing and fermentation operations. Academic research institutions also increased investment in environmental phage applications targeting antibiotic-resistant bacterial contamination in natural ecosystems. 

MARKET DYNAMICS

Driving Factor

Rising prevalence of antimicrobial-resistant bacterial infections.

The increasing burden of antibiotic-resistant bacterial infections remains the primary growth driver for the phage therapy market. During 2024, more than 4.95 million deaths globally were associated with antimicrobial resistance, while over 2.8 million antibiotic-resistant infections occurred annually in the United States alone. Healthcare institutions increasingly adopted alternative antibacterial therapies due to declining antibiotic effectiveness against multidrug-resistant pathogens. Human health applications accounted for 54% of phage therapy development activities during 2024. Personalized phage cocktails targeting bacterial strains such as Pseudomonas aeruginosa and Escherichia coli improved treatment precision by 37% in laboratory studies. Government-supported antimicrobial resistance programs also increased biotechnology collaboration activity by 23%, accelerating clinical development pipelines for therapeutic bacteriophage products globally.

Restraining Factor

Regulatory complexity and production standardization issues.

The phage therapy market faces significant challenges related to regulatory approval procedures and manufacturing standardization. Approximately 46% of biotechnology companies reported difficulties navigating inconsistent regulatory frameworks across international healthcare markets during 2024. Phage therapy products require highly specific bacterial targeting, making large-scale manufacturing and quality control more complex compared to conventional antibiotics. Standardized bacteriophage purification procedures increased production costs by 19% during clinical development stages. Healthcare providers also expressed concerns regarding phage stability, dosing consistency, and bacterial resistance adaptation. Limited reimbursement policies and restricted clinical adoption further slowed commercialization efforts across several healthcare systems.

Expansion of personalized precision bacteriophage therapies.

Opportunity

Personalized bacteriophage treatment platforms present major opportunities for the global phage therapy market. AI-assisted microbial analysis improved pathogen identification accuracy by 29% during 2024, enabling customized phage cocktail development for patient-specific bacterial infections. More than 41% of new bacteriophage research programs focused on precision-targeted therapies during 2024. Genomic sequencing advancements reduced bacterial analysis turnaround times by 24%, accelerating clinical treatment customization. Human health applications remain the largest opportunity area due to increasing multidrug-resistant bacterial infections globally. Food industry applications also expanded significantly, with bacteriophage products reducing Salmonella and Listeria contamination rates by 31% in food processing environments.

Limited clinical awareness and bacterial specificity constraints.

Challenge

The phage therapy market continues facing challenges associated with limited clinical familiarity and narrow bacterial targeting specificity. Approximately 38% of healthcare professionals reported insufficient clinical knowledge regarding bacteriophage treatment protocols during 2024. Phage therapies require precise bacterial identification before treatment, increasing diagnostic complexity and treatment preparation time. Bacterial mutations and evolving resistance mechanisms also affected long-term therapeutic consistency in certain laboratory studies. Manufacturing personalized phage cocktails for individual infections increased logistical complexity by 21% compared to broad-spectrum antibiotic production. Clinical trial data remained limited for several therapeutic indications due to small patient populations and specialized treatment approaches.

• Download Free Sample to learn more about this report

PHAGE THERAPY MARKET REGIONAL INSIGHTS

• North America

North America accounted for approximately 39% of the global phage therapy market during 2024 due to advanced biotechnology infrastructure and increasing antimicrobial resistance research activity. The United States represented nearly 58% of worldwide clinical bacteriophage development programs, supported by more than 48 active phage therapy studies during the year. Human health applications dominated regional market activity due to rising multidrug-resistant bacterial infections and increasing healthcare investments. More than 2.8 million antibiotic-resistant infections occur annually in the United States, significantly strengthening demand for alternative antibacterial therapies.

Precision bacteriophage cocktails targeting Pseudomonas aeruginosa and Staphylococcus aureus represented 44% of active therapeutic programs across North American biotechnology companies. AI-assisted bacterial analysis technologies improved pathogen targeting accuracy by 29% during 2024. Canada also expanded microbial biotechnology research through government-funded antimicrobial resistance initiatives and academic collaborations. Food safety applications gained increasing adoption across North America, with bacteriophage products reducing bacterial contamination rates by 31% in selected food processing operations. Regulatory agencies also increased compassionate-use approvals for severe bacterial infection cases resistant to conventional antibiotics.

• Europe

Europe represented approximately 31% of global phage therapy market activity during 2024 due to strong infectious disease research infrastructure and supportive antimicrobial resistance policies. France, Belgium, Poland, and Georgia remained major regional centers for bacteriophage research and therapeutic applications. Human health programs accounted for 51% of European phage therapy activities because of increasing multidrug-resistant bacterial infection concerns. Compassionate-use bacteriophage therapies increased by 26% across European healthcare institutions during 2024. Academic biotechnology collaborations expanded significantly, while government-supported antimicrobial resistance research programs increased by 18%.

Europe also strengthened regulatory frameworks supporting experimental bacteriophage treatment pathways for severe clinical cases. Food industry applications gained traction due to strict food safety standards and increasing restrictions on chemical preservatives. Agricultural bacteriophage products targeting crop pathogens reduced bacterial infection rates by 28% in selected European farming studies. Sustainable livestock management initiatives also encouraged phage-based alternatives to conventional antibiotics within poultry and cattle production systems. Advanced genomic sequencing capabilities improved bacteriophage selection precision across European clinical and industrial biotechnology sectors.

• Asia-Pacific

Asia-Pacific emerged as one of the fastest-expanding phage therapy markets during 2024 due to increasing antimicrobial resistance prevalence and biotechnology infrastructure investments. The region accounted for approximately 22% of global phage therapy activity, with China, Japan, South Korea, and India leading research and development initiatives. Human health and aquaculture applications represented major growth segments because of rising bacterial infection management requirements. China significantly expanded bacteriophage biotechnology research programs during 2024 through government-supported precision medicine initiatives. Aquaculture industries across China, Vietnam, and Indonesia increased phage therapy adoption by 18% to reduce antibiotic usage in seafood farming operations.

India also expanded academic research into bacteriophage therapies targeting multidrug-resistant tuberculosis and hospital-acquired bacterial infections. Asia-Pacific biotechnology firms increasingly invested in AI-driven bacteriophage discovery platforms and synthetic biology technologies. Agricultural applications also expanded significantly, with bacteriophage products reducing crop bacterial infections by 24% in controlled studies. Food safety bacteriophage solutions gained increasing commercial adoption due to rising processed food production and export quality requirements across regional manufacturing sectors.

• Middle East & Africa

Middle East & Africa accounted for approximately 8% of global phage therapy market activity during 2024 due to increasing healthcare modernization and infectious disease management initiatives. The United Arab Emirates, Saudi Arabia, South Africa, and Egypt remained key regional markets for microbial biotechnology development. Human health applications represented nearly 49% of regional phage therapy activities because of rising concerns regarding antimicrobial resistance and hospital-acquired infections. Healthcare institutions across the Gulf region expanded investments in precision medicine technologies and advanced infectious disease treatment programs during 2024.

Academic biotechnology collaborations increased by 16%, particularly in microbial genomics and bacteriophage research. South Africa also strengthened research into phage-based therapies targeting tuberculosis-related bacterial infections. Food safety and agricultural biotechnology applications gained increasing interest due to growing food security concerns across Middle East & Africa. Bacteriophage products targeting foodborne pathogens improved microbial contamination control efficiency by 22% in selected food processing environments. Aquaculture and livestock industries also explored phage-based alternatives to antibiotics to improve export compliance and animal health management standards.

LIST OF TOP PHAGE THERAPY COMPANIES

• NPO Microgen
• Proteon Pharmaceuticals
• Phagelux
• Intralytix
• Micreos
• Eliava BioPreparations
• Locus Biosciences,Inc
• Pharmex Group,LLC
• Pherecydes Pharma
• APS Biocontrol Ltd. (APS)
• Qingdao Phagepharm Bio-tech
• Fixed-Phage Limited
• Zeptometrix
• Phage International, Inc.
• MicroMir
• iNtODEWORLD, Inc.
• NEXTBIOTICS
• Armata Pharmaceuticals, Inc.
• Innophage
• Adaptive Phage Therapeutics
• TechnoPhage

Top 2 Companies With Highest Market Share

• Adaptive Phage Therapeutics: Accounted for approximately 14% of active global therapeutic bacteriophage clinical development programs during 2024.
• Armata Pharmaceuticals, Inc.: Represented nearly 11% of global phage therapy clinical pipeline activity during 2024.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The phage therapy market continues attracting strong biotechnology investments due to increasing antimicrobial resistance and rising demand for precision antibacterial treatments. More than 180 active phage therapy clinical and preclinical programs operated globally during 2024, creating substantial opportunities for biotechnology firms and healthcare research institutions. North America remained the leading investment region with 39% of total global phage therapy activities. AI-assisted bacteriophage discovery platforms improved microbial targeting accuracy by 29%, encouraging investments in computational biology and genomic sequencing technologies. Human health applications represented 54% of market activity due to increasing multidrug-resistant bacterial infections worldwide.

Government-funded antimicrobial resistance initiatives also increased biotechnology collaborations by 23% during 2024. Food safety applications created significant opportunities as bacteriophage products reduced Salmonella and Listeria contamination rates by 31% across industrial food processing environments. Aquaculture industries increased phage therapy integration by 18% to reduce antibiotic dependency and strengthen export compliance. Personalized bacteriophage cocktails targeting patient-specific infections also attracted strong investment attention because of improved bacterial elimination effectiveness and precision therapeutic potential. Asia-Pacific biotechnology infrastructure expansion further supported global phage therapy investment opportunities.

NEW PRODUCT DEVELOPMENT

Phage therapy companies increasingly focused on engineered bacteriophage technologies, personalized phage cocktails, and AI-assisted bacterial targeting systems during 2024. Synthetic biology advancements improved bacteriophage engineering precision by 26%, enabling development of highly specific antimicrobial therapies targeting multidrug-resistant pathogens. Personalized phage cocktail products increased by 34% within clinical research pipelines due to enhanced bacterial genome sequencing capabilities. AI-integrated microbial analysis platforms improved pathogen identification accuracy by 29%, accelerating therapeutic selection and reducing diagnostic preparation times. Biotechnology firms also developed CRISPR-enhanced bacteriophage technologies capable of improving bacterial targeting efficiency above 92% in laboratory studies.

Human therapeutic applications targeting Pseudomonas aeruginosa and Staphylococcus aureus remained primary development priorities. Food safety bacteriophage products gained increasing commercial adoption due to rising processed food contamination concerns globally. New phage formulations reduced foodborne bacterial contamination rates by 31% across meat and dairy processing facilities. Aquaculture and agricultural biotechnology sectors also expanded development of bacteriophage products targeting fish pathogens and crop bacterial diseases. Cold-chain stable phage formulations improved product transportation efficiency by 18%, strengthening international commercialization potential for bacteriophage therapeutics and microbial control solutions.

FIVE RECENT DEVELOPMENTS (2023-2025)

• In 2025, more than 180 active phage therapy clinical and preclinical programs operated globally due to increasing antimicrobial resistance research investments.
• In 2024, personalized bacteriophage cocktail therapies increased by 34% across biotechnology development pipelines targeting multidrug-resistant bacterial infections.
• In 2024, AI-assisted bacteriophage screening technologies improved bacterial targeting accuracy by 29% within precision antimicrobial research programs.
• In 2024, food industry bacteriophage products reduced Salmonella and Listeria contamination rates by 31% across selected industrial food processing environments.
• In 2023, aquaculture producers increased bacteriophage therapy adoption by 18% to reduce antibiotic usage within commercial seafood farming operations.

REPORT COVERAGE OF PHAGE THERAPY MARKET

The phage therapy market report provides comprehensive analysis of antimicrobial resistance trends, bacteriophage research activities, biotechnology innovation, and clinical development programs across global healthcare and industrial sectors. The report evaluates more than 180 active phage therapy programs operating worldwide during 2024 while analyzing therapeutic effectiveness, bacterial targeting specificity, and regulatory developments. Human health applications accounted for 54% of total market activity and are extensively covered within the report scope. The report includes segmentation analysis covering dsDNA bacteriophages, ssDNA bacteriophages, ssRNA bacteriophages, and engineered synthetic phage technologies. Application analysis evaluates human health, food safety, aquaculture, agriculture, animal health, and industrial biotechnology sectors based on adoption rates and microbial control efficiency.

Regional analysis covers North America, Europe, Asia-Pacific, and Middle East & Africa according to biotechnology infrastructure, antimicrobial resistance prevalence, and healthcare research investments. Competitive analysis assesses leading phage therapy companies based on clinical pipelines, biotechnology partnerships, intellectual property strategies, and personalized bacteriophage platform development. The report also examines AI-assisted microbial targeting technologies, genomic sequencing advancements, synthetic biology integration, and compassionate-use bacteriophage treatment programs. Investment trends, regulatory frameworks, and emerging commercial opportunities within the global phage therapy market are comprehensively analyzed throughout the report coverage.